Jan 19 2026

george

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

Here is an open-access article describing the efficacy of vonicog alfa versus plasma-derived VWF: Horvais V, Ternisien C, Denis-Le-Sève J, et al. Vonicog alfa versus plasma-derived von Willebrand factor during hospitalization: results of an observational retrospective multicenter study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2779-9176. PMID: 41529718. Abstract Available products for the treatment of von Willebrand […]

read more

Comments (0)

Bleeding Disorders

Jan 16 2026

george

Case: Thrombocytopenia

In a January 14, 2026 Diagnostic Equity post, an inquirer asked, “I was diagnosed with thrombocytopenia in 2024. I typically just go with the flow of what my doc and the nurse say. What are the lab tests that can help explain why my platelets are low, and how often should my platelets be monitored? […]

read more

Comments (0)

Bleeding Disorders

Jan 11 2026

george

Review: The Effect of Exercise on Bleeding Disorders

This year is the 100th anniversary of the first VWD description, prompting several VWD updates, including Giuffrida AC, Gandini G, Focosi D, Franchini M. Impact of exercise/sport on well-being in von Willebrand disease and other congenital bleeding disorders: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9762. PMID: 41512904 available from your medical library. Abstract Worldwide, […]

read more

Comments (0)

Bleeding Disorders

Jan 10 2026

george

Review: Desmopressin Therapy in Bleeding Disorders

Here is a 2025 open-access review that describes DDAVP Rx in hemophilia and VWD:  Reardon B, Pasalic L, Favaloro EJ. A review of desmopressin use in bleeding disorders: an unsung hero? Biomolecules. 2025;15:967. doi: 10.3390/biom15070967. PMID: 40723839; PMCID: PMC12292229. Abstract As a synthetic analogue of vasopressin, desmopressin or DDAVP has well-established hemostatic properties. We present […]

read more

Comments (0)

Bleeding Disorders

Jan 9 2026

george

VWD Type 2a Review

For an update on VWD type 2A, check with your medical library for Seidizadeh O, Baronciani L, Mannucci PM, Peyvandi F. Von Willebrand disease type 2A: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9989. PMID: 41453393. Abstract Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding […]

read more

Comments (0)

Bleeding Disorders

Dec 27 2025

george

Clinical Trial: Thrombin Generation Test Predicts Breakthrough Bleeding in Emicizumab Prophylaxis

Check with your medical library to obtain this clinical trial pre-publication: Pelzer FJ, Ertekin EI, Oleshko O, et al. Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis. Haematologica. 2025. doi: 10.3324/haematol.2025.288115. PMID: 41230703. Abstract Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against […]

read more

Comments (0)

Bleeding Disorders

Dec 11 2025

george

Anesthesiologists’ Approach to Perioperative Bleeding Management

ASH ’25 Report from Dr. Wolfgang Miesbach: Perioperative Bleeding Management: What 1,030+ U.S. Anesthesiologists Think About Current Challenges 50.6% practiced primarily at academic medical centers, while 42.3% worked in community hospitals, with additional representation from military/VA hospitals (3.7%). Nearly half (48.4%) worked at Level I trauma centers. The Progress… Prothrombin complex concentrates (PCCs) have become […]

read more

Comments (0)

Bleeding Disorders

Dec 11 2025

george

Hemophilia Rx: “Paradox of Choice”

An ASH ’25 report from Dr. Wolfgang Miesbach: The “Paradox of Choice” is very real in Haemophilia right now.  I just caught Dr. Mark Reding’s insightful presentation at ASH25, and it really highlighted that having more options doesn’t actually make the decision easier. In fact, it makes it harder. We’re looking at a massive toolkit […]

read more

Comments (0)

Bleeding Disorders

Dec 8 2025

george

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

David Kuter gave this presentation at ASH 2025: Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression. Increase Platelet Production The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct […]

read more

Comments (0)

Bleeding Disorders

Dec 1 2025

george

November 2025 QQ Summary: Historic Coag Factor Nomenclature

Our November Quick Question summary about Stuart-Prower Factor, linked to a 2023 article by Dave McGlasson about coagulation factor nomenclature. The summary and McGlasson’s article attracted a comment from Dr. Emmanuel Favaloro, which described the nomenclature of traditional and current VWF activity assays.  Dr. Favaloro cited three open-access articles on this topic (click to obtain the […]

read more

Comments (0)

Blog